patients scoring ≤10mm (16.1%), corresponding to a difference of up to 4.7% versus other PGAs. Similar results were found for the ≤20 cut-off (Table 1) . By using different PGA's formulations the rates of remission calculated with different indices can vary between 4.7% and 6.7% (Table 2) . Bland-Altman chart confirmed the low agreement between ACR/EULAR formulation and the other PGA formulations (p<.05), except for the DAS "general health" (p=.054). 1 Quality of life (Qol) in patients with RA may be substantially impacted by their inability to perform daily activities, a shift in family roles, more restricted employment opportunities, increased financial burden and social dependency and reduced recreational activities. Objectives: To investigate the Qol among RA patients and its association with demographic and socioeconomic details. Methods: This is a cross-sectional study conducted in a rheumatology outpatient clinic in Malaysia. Patients who fulfilled 2010 ACR/ EULAR classification criteria for RA were asked to answer WHOQOL-BREF questionnaire and specific questions on demographics and socio-economic details, during their attendance to rheumatology clinics. WHOQOL-BREF is a self-report quality of life questionnaire on individual's perception of quality of life and health, physical health, psychological, social relationships and environment domains. Data was analysed using SPSS 20. Student's t-test was used to analyse the mean difference between two groups and chi-square test was used to analyse between 2 categorical data. Pearson correlation was used to analyse correlation between two groups of continuous data. p<0.05 was considered significant. Results: The mean age of patients in this study was 53.10 (±14.3) years, with majority being females (80.4%) and married (70.6%). Half of the patients were Malays (49.0%). 51.0% rated overall quality of life as good and 41.2% rated overall health as satisfied. The mean transformed scores were 55.2 (±15.9) in physical health, 57.3 (±15.9) in psychological, 59.2 (±18.1) in social relationships and 58.2 (±15.2) in environment domains. There were significant differences in the transformed scores for Malay (65.5±15.9) and non-Malay (53.1±18.2) in the social relationship domain; t (49) =2.58, p=0.01, and for education at secondary level and above (65.9±14.9) and primary level (48.0±16.6), t(49)=-3.87, p<0.01. We found no significant association between race and education level; 17 (53.1%) Malays and 15 (46.9%) non-Malays had education level of secondary and higher, X 2 (1, N=51) =0.58, p=0.48. Patients with household income of less than RM 3, 000 had significantly lower scores compared to those with higher household income, in overall perception of quality of life (3.3±0.9 vs 4.0±0.6; t(49)=-2.8, p<0.01), overall perception of health (2.9±0.9 vs 3.6±0.7, t(49)=-2.97, p<0.01), physical health domain (51.2±16.2 vs 63.8±11.6, t(49)=-2.78, p=0.01) and psychological domain (53.3±16.3 vs 66.1±10.9, t(49)=-2.85, p=0.01).
Conclusions:
Patients with RA perceived their Qol to be moderate in all domains. Social relationship was perceived to be better in Malays and patients with higher educational level. Low income was significantly associated lower overall quality of life and health, physical and psychological health. Table  1 . 29 patients (%2.4) were diagnosed as ILD with regard to CT findings. Patients with ILD were older (64.5±6.7 vs 60.6±10.1, p=0.039) and more frequently positive for rheumatoid factor (RF) (25/27 (%92.6) vs 77/121 (%63.3), p=0.003) than patients without ILD. ILD was detected before beginning of biologics in 11 (37.9%) patients and during biologic treatment in 18 (62.1%) patients. Honeycombing was seen in 10 (34.5%) patients. First choice of biologic agent was RTX in 10 (34.5%) and TNFi in 19 (65.5%) patients. In ILD patients, mean follow-up duration was 51±31 months and first biologic was switched to another in 16 (55.2%) of patients. At the last follow-up visit 19 (65.5%) patients were on rituximab, 3 (10.3%) patients were on abatacept and 7 (24.1%) were on TNFi. Small airway disease was detected in 19 (9.3%) patients. History of smoking was present in only 4 (21.0%) of patients with small airway disease. 6 .0], SDAI-26 (21;34)), positive for ACCP (75%)/RF (79%), who were non-responders to MTX at least 15 mg/week and/or other synthetic DMARDs and bDMARDs. TOFA therapy was started in all pts with dose 5 mg BID per os followed by the dose escalation to 10 mg BID in 8 (29%) pts. TOFA used in combination with MTX in 27 (96%) pts, leflunomide in 1 (4%). Low-dose oral corticosteroids (<10 mg/day prednisone or equivalent) were received by 9 (35%) pts. Remission or LDA was achieved in 55% pts (DAS28), 77% (SDAI). At baseline the most of pts had multiple CVRF and subclinical organ damage (arterial hypertension-67%, overweight-57%, abdominal obesity-61%, physical inactivity-64%, smokers/ex-smokers-25%/21%, menopausal status-59%, DM type 2-7%, mSCORE≥5%>21%, subclinical carotid atherosclerosis-64%, cardiac heart failure with preserved ejection fraction-7%. Cardioprotective therapy received 16 (57%) pts (beta-blockers-7, angiotensin II receptor type 2/ACE inhibitors-11, statins-11, dihydropyridine calcium channel blockers-7).
THU0147 THORAX CT FINDINGS IN A LARGE COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS: HUR-BIO REAL LIFE RESULTS
Results: There was no difference in heart rate (HR), QTc interval duration, QRS duration measured by 12-lead ECG in RA pts treated with TOFA (table 1) . However, an increase in PQ interval duration was observed (p=0,04). There were significantly decrease of mean HR (p<0,003), increase of QRS duration (p<0,03), QTc (p<0.03), night QTc (p<0,02) in 24 h ECG ambulatory recording. HR, PQ, QTc duration were changed independently of beta-blockers therapy. The number of pts with QTc≥440 ms increased from 11% to 21% (p>0.05). A change in QTc duration correlated negatively with dynamics of DAS 28, SDAI (r=-0,4, p<0,05), DM (r=0,5, p<0,02), dBP (r=-0,4, p<0,04). There were also significantly increase number of ventricular premature beats (p<0,03). Background: Methotrexate (MTX) is used as an anchor drug for the treatment of rheumatoid arthritis (RA). Patients with RA have a modestly increased risk of developing lymphoproliferative disorders (LPD). Furthermore, although sometimes spontaneous regression occurs after withdrawal of MTX, LPD developed during the treatment with MTX is broadly defined as MTX-associated LPD (MTX-LPD). Objectives: To characterize the risk factors concerning MTX-LPD and to consider optimal treatment after occurrence of LPD in patients with RA. Methods: We retrospectively evaluated 51 RA patients with LPD from 2006 to 2015 in our institution. MTX-LPD patients were divided into two groups; regressive LPD after MTX cessation (N=27) and persistent LPD though MTX was tapered (N=24), and the clinical characteristics, pathology and treatment outcomes were compared. EBV infection and IL-6 receptor (IL-6R) expression were analyzed by in situ hybridization and immunohistochemistry. Results: There was no significant difference in disease duration, stage, disease activity of RA, the positive rate of Epstein-Barr virus-encoded small RNAs, EBERs (42.7 vs 50.0%) and treatment with TNF-inhibitors (40.7 vs 45.8%) between regressive LPD and persistent LPD. Age of LPD onset (59.1 vs 68.3), CRP (2 vs 5 mg/dl) and the weekly MTX dose (10.9 vs 8.4 mg/w) significantly differed between the groups. Of note, IL-6R was highly expressed in both group (75.0 vs 66.7%). Among regressive LPD, 3 patients developed DLBCL later. persistent LPD showed poorer prognosis and worse mortality than regressive LPD. An older age and anemia were poor prognostic factors. Of 51 patients, 41% achieved sustained low disease activity (LDA) with other DMARDs except MTX. Nine of 10 patients refractory to DMARDs were controlled by tocilizumab (TCZ) and kept LDA. Conclusions: Taken together, it seems unreasonable to be lump the persistentgroup into the same category as MTX-LPD. The high expression rate of IL-6R and the high responsiveness to TCZ suggest that IL-6/IL-6R is likely to play a role in the development of LPD in patients with RA. 
